This study is testing a new medication called ABSK112 for people with locally advanced or metastatic non-small cell lung cancer (NSCLC). The main goals are to see how safe ABSK112 is, how well your body handles it, and how it moves through your system. Researchers will also look for early signs that ABSK112 might help fight cancer. You would take ABSK112 either once or twice a day. To join, you need to be at least 18 years old and have NSCLC that has been confirmed by a biopsy. Some participants will specifically have NSCLC with an EGFR Exon20ins biomarker. The study plans to enroll 164 participants, but its current recruitment status is unclear.

Study design

This is a first-in-human, multicenter, non-randomized, open-label study. It will involve a dose escalation part followed by an expansion part.

What's involved

In the escalation part, you would receive a single dose of oral ABSK112 on Day 1 of the first cycle, then continuously receive it once or twice daily in later cycles. In the expansion part, you would be treated at a selected dose level.

Compensation

Not stated in the trial record.

Follow-up

Your health will be monitored for side effects from the time you sign the consent form until 30 days after your last dose of ABSK112, for up to 50 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.